サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1761747

残留DNA検査の世界市場：オファリング別、検査タイプ別、技術別、用途別、エンドユーザー別、地域別 - 2030年までの予測

Residual DNA Testing Market by Product & Service (Consumable, Instrument & Software), Technology (PCR), Test Type (Raw, Final, Bulk Lot Release Testing), Application (mAb, CGT, Vaccine), End User (Pharma & Biotech, CRO & CDMO) - Global Forecast to 2030

出版日
ページ情報
英文 357 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.09円
残留DNA検査の世界市場：オファリング別、検査タイプ別、技術別、用途別、エンドユーザー別、地域別 - 2030年までの予測
出版日: 2025年07月01日
発行: MarketsandMarkets
ページ情報: 英文 357 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

残存DNA検査の市場規模は、予測期間中に6.0%のCAGRで拡大し、2025年の2億8,000万米ドルから2030年には3億7,000万米ドルに達すると予測されています。

この市場の拡大には、生物製剤やバイオシミラーの承認頻度の増加、バイオ医薬品の製造を管理する厳格な規制枠組みの導入など、複数の要因が寄与しています。さらに、残留DNA検査に関連する技術の進歩は、予測期間を通じて市場の成長をさらに促進すると予想されます。

調査範囲
調査対象年 2023年～2030年
基準年 2024年
予測期間 2025年～2030年
検討単位 金額（100万米ドル）
セグメント オファリング別、検査タイプ別、技術別、用途別、エンドユーザー別、地域別
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

技術別では、市場はPCR、閾値アッセイ、DNAプローブハイブリダイゼーション、その他の技術に区分されます。2024年、ポリメラーゼ連鎖反応（PCR）分野は、分子診断における極めて重要な役割を反映し、市場で最大のシェアを占めました。この大きな市場シェアは、PCRが提供する高い感度と特異性に起因しており、微量の残留DNAでも正確に検出することができます。その結果、PCRは偽陽性のリスクを効果的に最小化し、正確な検査結果を保証する上で重要な要素となります。さらに、PCR技術の汎用性は、その普及に重要な役割を果たしています。PCRは様々なタイプの検査に容易に適応でき、バイオ医薬品用途の広い範囲に適用できます。この適応性は、そのスケーラビリティと相まって、PCRが小規模な調査から大規模な臨床試験まであらゆるものに採用されることを可能にし、バイオ医薬品業界の進化するニーズに対応しています。その卓越した性能特性と柔軟な用途により、PCRセグメントは分子生物学と診断学の進歩の礎であり続けています。

残留DNA検査サービス市場は、製薬・バイオテクノロジー企業と学術・研究機関の2つの主要セグメントに分類されます。2024年現在、製薬・バイオテクノロジー企業セグメントが市場で最大のシェアを占めています。この大幅な成長の背景には、がん、自己免疫疾患、遺伝的疾患など、さまざまな疾患の治療を目的とした革新的な治療法である生物製剤の開発が重視されるようになっていることがあります。業界の発展に伴い、製薬・バイオテクノロジー企業は厳しい規制基準の遵守を求められており、製造プロセス全体に関する包括的なデータの提供が義務付けられています。これには、生物学的製剤の安全性と有効性を確保するための厳格な試験と検証も含まれます。その結果、徹底した品質検査と規制当局の承認が最重要となり、残留DNA検査サービスの需要が高まっています。これらのサービスは、生物製剤に残存するDNAを同定・定量し、製品が安全性ガイドラインを満たし、患者にリスクをもたらす可能性のある汚染物質がないことを保証する上で重要な役割を果たします。さらに、企業が高度なバイオテクノロジーの研究開発に投資するにつれて、信頼性が高く正確な検査方法に対する需要が高まり続けています。この動向は、残留DNA検査サービスの市場をさらに拡大し、製薬業界におけるその重要な役割を浮き彫りにしています。同分野が技術革新とコンプライアンスに努めるにつれ、こうした検査サービスの重要性は高まる可能性が高く、医学と患者の安全性の向上におけるその価値が強調されます。

2024年には、北米が市場の支配的勢力に浮上しましたが、これは主に主要な業界リーダーの強い存在感と、生物製剤の革新と開発を目指した研究イニシアチブの顕著な拡大によるものです。この成長は、ライフサイエンス分野における研究開発投資の大幅な増加に起因しており、その結果、残留DNA検査製品およびサービスの需要が高まっています。その他の特典として、この地域には製薬会社、バイオテクノロジー企業、学術機関など数多くの世界企業が集積しており、それらが一体となって市場での主導的地位を高めています。このような協力的な環境はイノベーションを促進し、生物製剤の進歩を加速させ、ライフサイエンス研究開発の極めて重要な拠点としての北米の役割をさらに強固なものにしています。

当レポートでは、世界の残留DNA検査市場について調査し、オファリング別、検査タイプ別、技術別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 顧客のビジネスに影響を与える動向/混乱
  • 価格分析
  • バリューチェーン分析
  • エコシステム分析
  • 投資と資金調達のシナリオ
  • 技術分析
  • 特許分析
  • 2025年～2026年の主な会議とイベント
  • 規制分析
  • ポーターのファイブフォース分析
  • 主要な利害関係者と購入基準
  • AI/生成AIが残留DNA検査市場に与える影響
  • 貿易データ分析
  • 2025年の米国関税が残留DNA検査市場に与える影響

第6章 残留DNA検査市場（オファリング別）

  • イントロダクション
  • 製品
  • サービス

第7章 残留DNA検査市場（検査タイプ別）

  • イントロダクション
  • 最終製品リリーステスト
  • バルクロットリリーステスト
  • 原材料試験

第8章 残留DNA検査市場（技術別）

  • イントロダクション
  • ポリメラーゼ連鎖反応
  • 閾値アッセイ
  • DNAプローブハイブリダイゼーション
  • その他

第9章 残留DNA検査市場（用途別）

  • イントロダクション
  • モノクローナル抗体
  • 細胞・遺伝子治療
  • ワクチン
  • その他

第10章 残留DNA検査製品市場（エンドユーザー別）

  • イントロダクション
  • 製薬・バイオテクノロジー企業
  • CROとCDMO
  • 学術研究機関

第11章 残留DNA検査サービス市場（エンドユーザー別）

  • イントロダクション
  • 製薬・バイオテクノロジー企業
  • 学術研究機関

第12章 残留DNA検査市場（地域別）

  • イントロダクション
  • 北米
    • 北米のマクロ経済見通し
    • 米国
    • カナダ
  • 欧州
    • 欧州のマクロ経済見通し
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • アジア太平洋のマクロ経済見通し
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他
  • ラテンアメリカ
    • ラテンアメリカのマクロ経済見通し
    • ブラジル
    • メキシコ
    • その他
  • 中東
    • 中東のマクロ経済見通し
    • GCC諸国
    • その他中東
  • アフリカ
    • 慢性疾患の罹患率の上昇とバイオ医薬品セクターへの資金増加が市場成長を促進
    • アフリカのマクロ経済見通し

第13章 競合情勢

  • イントロダクション
  • 主要参入企業の戦略/強み
  • 収益分析、2020年～2024年
  • 市場シェア分析、2024年
  • 企業評価マトリックス：主要参入企業、2024年
  • 企業評価マトリックス：スタートアップ/中小企業、2024年
  • 企業評価と財務指標
  • ブランド/製品比較
  • 競合シナリオ

第14章 企業プロファイル

  • 主要参入企業
    • THERMO FISHER SCIENTIFIC INC.
    • CHARLES RIVER LABORATORIES
    • F. HOFFMANN-LA ROCHE LTD.
    • MERCK KGAA
    • MARAVAI LIFESCIENCES
    • EUROFINS SCIENTIFIC
    • BIO-RAD LABORATORIES, INC.
    • QIAGEN
    • FUJIFILM CORPORATION
    • SGS SOCIETE GENERALE DE SURVEILLANCE SA.
    • HILLGENE BIOPHARMA CO., LTD.
    • REVVITY
    • INTERTEK GROUP PLC
    • SARTORIUS AG
    • LONZA
    • WUXI APPTEC
  • その他の企業
    • TRANSGEN BIOTECH CO., LTD.
    • EAGLEBIO
    • YEASEN
    • ACROBIOSYSTEMS
    • CREATIVE BIOGENE
    • MINERVA BIOLABS GMBH
    • CREATIVE PROTEOMICS
    • AVANCE BIOSCIENCES
    • GENERI BIOTECH

第15章 付録

図表

List of Tables

  • TABLE 1 RESIDUAL DNA TESTING MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • TABLE 3 RESIDUAL DNA TESTING MARKET: RISK ANALYSIS
  • TABLE 4 RESIDUAL DNA TESTING MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • TABLE 5 LIST OF FDA-APPROVED BIOSIMILAR PRODUCTS, 2022-2024
  • TABLE 6 KEY PRODUCT APPROVALS IN GENE THERAPY MARKET, 2022-2024
  • TABLE 7 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS, BY KEY PLAYER, 2022-2024 (USD MILLION)
  • TABLE 8 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA QUANTIFICATION KITS, BY REGION, 2022-2024 (USD MILLION)
  • TABLE 9 AVERAGE SELLING PRICE TREND OF PCR INSTRUMENTS, BY REGION, 2022-2024 (USD MILLION)
  • TABLE 10 RESIDUAL DNA TESTING MARKET: ROLE IN ECOSYSTEM
  • TABLE 11 MAJOR INVESTMENT AND FUNDING ACTIVITIES IN RESIDUAL DNA TESTING MARKET, BY KEY PLAYER, 2022-2025
  • TABLE 12 RESIDUAL DNA TESTING MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2024
  • TABLE 13 RESIDUAL DNA TESTING MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
  • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 RESIDUAL DNA TESTING MARKET: PORTER'S FIVE FORCES
  • TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
  • TABLE 20 KEY BUYING CRITERIA, BY END USER
  • TABLE 21 LIST OF KEY COMPANIES IMPLEMENTING AI/GEN AI IN RESIDUAL DNA TESTING MARKET
  • TABLE 22 RESIDUAL DNA TESTING MARKET: IMPORT DATA FOR HS CODE 9027, 2020-2024 (USD THOUSAND)
  • TABLE 23 RESIDUAL DNA TESTING MARKET: EXPORT DATA FOR HS CODE 9027, 2020-2024 (USD THOUSAND)
  • TABLE 24 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 25 PRODUCT/COMPONENT-RELATED TARIFFS FOR RESIDUAL DNA TESTING PRODUCTS
  • TABLE 26 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
  • TABLE 27 RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 28 RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 29 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 30 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 32 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 34 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 36 RESIDUAL DNA TESTING CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 37 NORTH AMERICA: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 EUROPE: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 LATIN AMERICA: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 MIDDLE EAST: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 GCC COUNTRIES: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 44 NORTH AMERICA: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 EUROPE: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 LATIN AMERICA: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 MIDDLE EAST: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 49 GCC COUNTRIES: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 RESIDUAL DNA TESTING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 56 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 58 RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 59 NORTH AMERICA: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 EUROPE: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 LATIN AMERICA: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 MIDDLE EAST: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 64 GCC COUNTRIES: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 EUROPE: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 LATIN AMERICA: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 70 MIDDLE EAST: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 71 GCC COUNTRIES: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 73 NORTH AMERICA: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 EUROPE: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 LATIN AMERICA: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 77 MIDDLE EAST: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 78 GCC COUNTRIES: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 80 RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 82 EUROPE: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 84 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 88 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 89 EUROPE: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 93 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 EUROPE: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 100 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 101 RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 102 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 EUROPE: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 107 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 108 RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 109 RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 110 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 EUROPE: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 115 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 117 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 EUROPE: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 121 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 122 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 RESIDUAL DNA TESTING MARKET FOR VACCINES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 124 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 EUROPE: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 129 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 130 RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 131 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 EUROPE: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 134 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 136 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 137 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 138 RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 139 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 140 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 142 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 144 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 146 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 147 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 149 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 151 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 152 RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 153 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 154 EUROPE: RESIDUAL DNA TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 156 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 158 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 159 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 160 RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 161 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 162 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 163 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 165 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 166 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 168 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 169 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 171 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 172 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 174 RESIDUAL DNA TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 175 RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 176 RESIDUAL DNA TESTING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 177 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 178 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 179 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 180 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 181 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 182 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 183 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 184 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 185 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 186 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 187 US: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 188 US: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 189 US: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 190 US: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 191 US: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 192 US: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 193 US: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 194 CANADA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 195 CANADA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 196 CANADA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 197 CANADA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 198 CANADA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 199 CANADA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 200 CANADA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 201 EUROPE: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 202 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 203 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 204 EUROPE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 205 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 206 EUROPE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 207 EUROPE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 208 EUROPE: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 209 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 210 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 211 GERMANY: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 212 GERMANY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 213 GERMANY: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 214 GERMANY: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 215 GERMANY: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 216 GERMANY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 217 GERMANY: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 218 UK: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 219 UK: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 220 UK: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 221 UK: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 222 UK: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 223 UK: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 224 UK: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 225 FRANCE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 226 FRANCE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 227 FRANCE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 228 FRANCE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 229 FRANCE: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 230 FRANCE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 231 FRANCE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 232 ITALY: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 233 ITALY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 234 ITALY: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 235 ITALY: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 236 ITALY: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 237 ITALY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 238 ITALY: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 239 SPAIN: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 240 SPAIN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 241 SPAIN: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 242 SPAIN: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 243 SPAIN: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 244 SPAIN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 245 SPAIN: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 246 REST OF EUROPE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 247 REST OF EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 248 REST OF EUROPE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 249 REST OF EUROPE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 250 REST OF EUROPE: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 251 REST OF EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,2023-2030 (USD MILLION)
  • TABLE 252 REST OF EUROPE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 253 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 254 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 255 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 257 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 258 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 259 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 260 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 261 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 262 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 263 CHINA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 264 CHINA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 265 CHINA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 266 CHINA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 267 CHINA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 268 CHINA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 269 CHINA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 270 JAPAN: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 271 JAPAN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 272 JAPAN: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 273 JAPAN: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 274 JAPAN: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 275 JAPAN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 276 JAPAN: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 277 INDIA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 278 INDIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 279 INDIA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 280 INDIA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 281 INDIA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 282 INDIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 283 INDIA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 284 SOUTH KOREA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 285 SOUTH KOREA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 286 SOUTH KOREA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 287 SOUTH KOREA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 288 SOUTH KOREA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 289 SOUTH KOREA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 290 SOUTH KOREA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 291 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 292 AUSTRALIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 293 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 294 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 295 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 296 AUSTRALIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 297 AUSTRALIA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 298 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 299 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 300 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 301 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 302 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 303 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 304 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 305 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 306 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 307 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 308 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 309 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 310 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 311 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 312 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 313 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 314 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 315 BRAZIL: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 316 BRAZIL: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 317 BRAZIL: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 318 BRAZIL: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 319 BRAZIL: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 320 BRAZIL: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 321 BRAZIL: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 322 MEXICO: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 323 MEXICO: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 324 MEXICO: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 325 MEXICO: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 326 MEXICO: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 327 MEXICO: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 328 MEXICO: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 329 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 330 REST OF LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 331 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 332 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 333 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 334 REST OF LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 335 REST OF LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 336 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 337 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 338 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 339 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 340 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 341 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 342 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 343 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 344 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 345 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 346 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 347 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 348 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 349 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 350 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 351 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 352 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 353 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 354 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 355 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 356 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 357 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 358 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 359 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 360 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 361 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 362 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 363 UAE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 364 UAE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 365 UAE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 366 UAE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 367 UAE: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 368 UAE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 369 UAE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 370 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 371 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 372 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 373 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 374 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 375 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 376 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 377 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 378 REST OF MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 379 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 380 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 381 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 382 REST OF MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 383 REST OF MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 384 AFRICA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 385 AFRICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 386 AFRICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 387 AFRICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 388 AFRICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 389 AFRICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 390 AFRICA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 391 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN RESIDUAL DNA TESTING MARKET
  • TABLE 392 RESIDUAL DNA TESTING MARKET: DEGREE OF COMPETITION
  • TABLE 393 RESIDUAL DNA TESTING MARKET: REGION FOOTPRINT
  • TABLE 394 RESIDUAL DNA TESTING MARKET: OFFERING FOOTPRINT
  • TABLE 395 RESIDUAL DNA TESTING MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 396 RESIDUAL DNA TESTING MARKET: TEST TYPE FOOTPRINT
  • TABLE 397 RESIDUAL DNA TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 398 RESIDUAL DNA TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS
  • TABLE 399 RESIDUAL DNA TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2021-MAY 2025
  • TABLE 400 RESIDUAL DNA TESTING MARKET: DEALS, JANUARY 2021-MAY 2025
  • TABLE 401 RESIDUAL DNA TESTING MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2025
  • TABLE 402 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 403 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 404 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 405 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS, JANUARY 2022-MAY 2025
  • TABLE 406 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 407 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
  • TABLE 408 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 409 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 410 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 411 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 412 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 413 MERCK KGAA: PRODUCTS/SERVICES OFFERED
  • TABLE 414 MERCK KGAA: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 415 MERCK KGAA: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 416 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
  • TABLE 417 MARAVAI LIFESCIENCES: PRODUCTS/SERVICES OFFERED
  • TABLE 418 MARAVAI LIFESCIENCES: DEALS, JANUARY 2022-MAY 2025
  • TABLE 419 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 420 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
  • TABLE 421 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022-MAY 2025
  • TABLE 422 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 423 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 424 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-MAY 2025
  • TABLE 425 QIAGEN: COMPANY OVERVIEW
  • TABLE 426 QIAGEN: PRODUCTS/SERVICES OFFERED
  • TABLE 427 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 428 FUJIFILM CORPORATION: COMPANY OVERVIEW
  • TABLE 429 FUJIFILM CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 430 SGS SOCIETE GENERALE DE SURVEILLANCE SA.: COMPANY OVERVIEW
  • TABLE 431 SGS SOCIETE GENERALE DE SURVEILLANCE SA.: PRODUCTS/SERVICES OFFERED
  • TABLE 432 HILLGENE BIOPHARMA CO., LTD.: COMPANY OVERVIEW
  • TABLE 433 HILLGENE BIOPHARMA CO., LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 434 REVVITY: COMPANY OVERVIEW
  • TABLE 435 REVVITY: PRODUCTS/SERVICES OFFERED
  • TABLE 436 REVVITY: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 437 INTERTEK GROUP PLC: COMPANY OVERVIEW
  • TABLE 438 INTERTEK GROUP PLC: PRODUCTS/SERVICES OFFERED
  • TABLE 439 SARTORIUS AG: COMPANY OVERVIEW
  • TABLE 440 SARTORIUS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 441 LONZA: COMPANY OVERVIEW
  • TABLE 442 LONZA: PRODUCTS/SERVICES OFFERED
  • TABLE 443 WUXI APPTEC: COMPANY OVERVIEW
  • TABLE 444 WUXI APPTEC: PRODUCTS/SERVICES OFFERED
  • TABLE 445 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 446 EAGLEBIO: COMPANY OVERVIEW
  • TABLE 447 YEASEN: COMPANY OVERVIEW
  • TABLE 448 ACROBIOSYSTEMS: COMPANY OVERVIEW
  • TABLE 449 CREATIVE BIOGENE: COMPANY OVERVIEW
  • TABLE 450 MINERVA BIOLABS GMBH: COMPANY OVERVIEW
  • TABLE 451 CREATIVE PROTEOMICS: COMPANY OVERVIEW
  • TABLE 452 AVANCE BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 453 GENERI BIOTECH: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 RESIDUAL DNA TESTING MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESIDUAL DNA TESTING MARKET: YEARS CONSIDERED
  • FIGURE 3 RESIDUAL DNA TESTING MARKET: RESEARCH DESIGN
  • FIGURE 4 RESIDUAL DNA TESTING MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
  • FIGURE 5 RESIDUAL DNA TESTING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 6 RESIDUAL DNA TESTING MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2024)
  • FIGURE 7 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2024)
  • FIGURE 8 RESIDUAL DNA TESTING MARKET: INSIGHTS FROM PRIMARIES
  • FIGURE 9 RESIDUAL DNA TESTING MARKET: TOP-DOWN APPROACH
  • FIGURE 10 RESIDUAL DNA TESTING MARKET: CAGR PROJECTIONS
  • FIGURE 11 RESIDUAL DNA TESTING MARKET: DATA TRIANGULATION
  • FIGURE 12 RESIDUAL DNA TESTING MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 REGIONAL ANALYSIS OF RESIDUAL DNA TESTING MARKET
  • FIGURE 19 INCREASE IN NUMBER OF BIOLOGICS AND BIOSIMILAR APPROVALS TO DRIVE MARKET
  • FIGURE 20 US AND FINAL PRODUCT RELEASE TESTING ACCOUNTED FOR LARGEST NORTH AMERICAN MARKET SHARE IN 2024
  • FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED LARGEST MARKET SHARE IN 2024
  • FIGURE 22 CHINA TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 23 RESIDUAL DNA TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 GLOBAL TOTAL PHARMACEUTICAL R&D SPEND, 2016-2030
  • FIGURE 25 RESIDUAL DNA TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • FIGURE 26 AVERAGE SELLING PRICE OF DNA QUANTIFICATION KITS, BY KEY PLAYER, 2024 (USD)
  • FIGURE 27 AVERAGE SELLING PRICE TREND OF PCR SYSTEMS, BY KEY PLAYER, 2022-2024 (USD)
  • FIGURE 28 AVERAGE SELLING PRICE OF RESIDUAL DNA TESTING PRODUCTS, BY REGION, 2024 (USD)
  • FIGURE 29 RESIDUAL DNA TESTING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 30 RESIDUAL DNA TESTING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 31 FUNDING AND NUMBER OF DEALS IN RESIDUAL DNA TESTING MARKET, 2021-2024
  • FIGURE 32 TOP APPLICANTS OF RESIDUAL DNA TESTING PATENTS, 2014-2024
  • FIGURE 33 RESIDUAL DNA TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • FIGURE 35 KEY BUYING CRITERIA, BY END USER
  • FIGURE 36 RESIDUAL DNA TESTING MARKET: KEY AI USE CASES
  • FIGURE 37 NORTH AMERICA: RESIDUAL DNA TESTING MARKET SNAPSHOT
  • FIGURE 38 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET SNAPSHOT
  • FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN RESIDUAL DNA TESTING MARKET, 2020-2024 (USD MILLION)
  • FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RESIDUAL DNA TESTING MARKET (2024)
  • FIGURE 41 RESIDUAL DNA TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 42 RESIDUAL DNA TESTING MARKET: COMPANY FOOTPRINT
  • FIGURE 43 RESIDUAL DNA TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 44 WEV/EBITDA OF KEY VENDORS
  • FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 46 RESIDUAL DNA TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 51 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT
  • FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 54 QIAGEN: COMPANY SNAPSHOT
  • FIGURE 55 FUJIFILM CORPORATION: COMPANY SNAPSHOT
  • FIGURE 56 SGS SOCIETE GENERALE DE SURVEILLANCE SA.: COMPANY SNAPSHOT
  • FIGURE 57 HILLGENE BIOPHARMA CO., LTD.: COMPANY SNAPSHOT
  • FIGURE 58 REVVITY: COMPANY SNAPSHOT
  • FIGURE 59 INTERTEK GROUP PLC: COMPANY SNAPSHOT
  • FIGURE 60 SARTORIUS AG: COMPANY SNAPSHOT
  • FIGURE 61 LONZA: COMPANY SNAPSHOT
  • FIGURE 62 WUXI APPTEC: COMPANY SNAPSHOT
目次
Product Code: BT 9405

The residual DNA testing market is projected to reach USD 0.37 billion by 2030 from USD 0.28 billion in 2025, at a CAGR of 6.0% during the forecast period. The expansion of this market is fueled by multiple factors, including the increasing frequency of approvals for biologics and biosimilars, as well as the implementation of rigorous regulatory frameworks governing the manufacture of biopharmaceutical products. Additionally, advancements in technologies related to residual DNA testing are anticipated to further bolster market growth throughout the forecast period.

Scope of the Report
Years Considered for the Study2023-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD Million)
SegmentsOffering, Technology, Test Type, Application, End User (Product), End User (Service), and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

By technology, the PCR segment accounted for the largest share of the residual DNA testing market in 2024.

By technology, the market is segmented into PCR, threshold Assays, DNA probe hybridization, and other technologies. In 2024, the Polymerase Chain Reaction (PCR) segment commanded the largest share of the market, reflecting its pivotal role in molecular diagnostics. This substantial market share can be primarily attributed to the high sensitivity and specificity offered by PCR, which enables the precise detection of even minute quantities of residual DNA. As a result, PCR effectively minimizes the risk of false positives, a critical factor in ensuring accurate test outcomes. Moreover, the versatility of the PCR technology plays a significant role in its widespread adoption. It can be easily adapted for various test types, making it applicable across a broad spectrum of biopharmaceutical applications. This adaptability, combined with its scalability, allows PCR to be employed in everything from small-scale research studies to large-scale clinical testing, catering to the evolving needs of the biopharmaceutical industry. With its exceptional performance characteristics and flexible applications, the PCR segment continues to be a cornerstone of advancements in molecular biology and diagnostics.

In 2024, by end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the residual DNA testing services market.

The residual DNA testing services market is categorized into two primary segments: pharmaceutical & biotechnology companies and academic & research institutes. As of 2024, the pharmaceutical & biotechnology companies segment holds the largest share of the market. This substantial growth can be attributed to the increasing emphasis on the development of biologics, which are innovative therapies aimed at treating a variety of diseases, including cancers, autoimmune disorders, and genetic conditions. As the industry evolves, pharmaceutical and biotechnology firms are required to adhere to stringent regulatory standards, which mandate the provision of comprehensive data concerning the entire manufacturing process. This includes the rigorous testing and validation of biological products to ensure their safety and efficacy. Consequently, the necessity for thorough quality inspections and regulatory approvals becomes paramount, driving the demand for residual DNA testing services. These services play a critical role in identifying and quantifying residual DNA left in biologics, ensuring that products meet safety guidelines and are free from contaminants that could pose risks to patients. Moreover, as companies invest in advanced biotechnological research and development, the demand for reliable and accurate testing methods continues to rise. This trend further augments the market for residual DNA testing services, highlighting its essential role in the pharmaceutical landscape. As the sector strives for innovation and compliance, the importance of these testing services will likely increase, underscoring their value in advancing medical science and patient safety.

In 2024, North America accounted for the largest share of the residual DNA testing market.

In 2024, North America emerged as the dominant force in the market, largely due to the strong presence of key industry leaders and a notable expansion in research initiatives aimed at innovating and developing biologics. This growth can be attributed to a significant increase in research and development investments within the life sciences sector, which, in turn, has escalated the demand for residual DNA testing products and services. Additionally, the region benefits from a concentration of numerous global entities, including pharmaceutical companies, biotech firms, and academic institutions, which collectively enhance its leadership position in the market. This collaborative environment fosters innovation and accelerates advancements in biologics, further solidifying North America's role as a pivotal hub for life sciences R&D.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
  • By Designation: CXOs and Directors- 30%, Managers- 45%, and Executives- 25%
  • By Region: North America -35%, Europe - 25%, Asia Pacific -15%, Latin America -10%, Middle East- 10%, and Africa- 5%

List of companies profiled in the report:

  • Thermo Fisher Scientific Inc. (US)
  • Merck KGaA (Germany)
  • Eurofins Scientific (Luxembourg)
  • Charles River Laboratories (US)
  • Bio-Rad Laboratories (US)
  • QIAGEN (Germany)
  • F. Hoffmann-La Roche Ltd (Switerland)
  • Maravai LifeSciences (US)
  • FUJIFILM Corporation (Japan)
  • SGS Societe Generale de Surveillance SA (Switzerland)
  • Jiangsu Hillgene Biopharma Co.,Ltd (China)
  • Revvity (US)
  • Intertek Group plc (UK)
  • WuXi AppTec (China)
  • Sartorius AG (Germany)
  • Lonza (Switzerland)

Research Coverage:

This research report categorizes residual DNA testing market by offering (products and services), technology (PCR, threshold assay, DNA probe hybridization, and other technologies), test type (final product release testing, bulk lot release testing, and final product release testing), application (monoclonal antibodies, cell & gene therapy, vaccines, and other applications), end user for products (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), end user for services (pharmaceutical & biotechnology companies and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The report offers an in-depth examination of the critical elements shaping the residual DNA testing market, including key drivers, constraints, challenges, and emerging opportunities. It presents a comprehensive analysis of leading industry players, detailing their business models, product and service offerings, strategic initiatives, new launches, acquisitions, and recent advancements pertinent to the residual DNA testing sector. Additionally, this report includes a competitive landscape assessment of emerging startups within the residual DNA testing ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the residual DNA testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following:

  • Analysis of key drivers (Increase in biologics and biosimilars approvals, stringent regulatory compliance requirements, technological advancements in DNA quantification and detection, increasing cell culture contamination risks, rising investments in R&D spending), restraints (high cost of advanced testing techniques, lack of standardization across testing protocols), opportunities (application in novel modalities such as mRNA vaccines, cell therapies, and gene therapies, growth opportunities in emerging markets, integration with continuous and accelerated bioprocessing, rising outsourcing to CROs and CDMOs), and challenges (complexity in sample preparation and assay validation) are influencing the growth of the residual DNA testing market.
  • Product Development/Innovation: Detailed insights on newly launched products of the residual DNA testing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the residual DNA testing market across varied regions.
  • Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the residual DNA testing market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Eurofins Scientific (Luxembourg), among others, offering products and services for the residual DNA testing market. Other companies in this market include TransGen Biotech Co., Ltd. (China), Vazyme International LLC (China), and EagleBio (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key sources of secondary data
      • 2.1.1.2 Key objectives of secondary research
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primaries
      • 2.1.2.2 Key objectives of primary research
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 MARKET ESTIMATION
      • 2.2.1.1 Company revenue analysis (bottom-up approach)
      • 2.2.1.2 Insights of primary experts
    • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 RESIDUAL DNA TESTING MARKET OVERVIEW
  • 4.2 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE AND COUNTRY
  • 4.3 RESIDUAL DNA TESTING PRODUCTS MARKET SHARE, BY END USER, 2024
  • 4.4 RESIDUAL DNA TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing number of biologics and biosimilar approvals
      • 5.2.1.2 Stringent regulatory compliance requirements
      • 5.2.1.3 Technological advancements in DNA quantification and detection
      • 5.2.1.4 Increasing risk of cell culture contamination
      • 5.2.1.5 Rising biopharmaceutical R&D investments
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs of advanced testing techniques
      • 5.2.2.2 Lack of standardization across testing protocols
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising number of applications in novel modalities
      • 5.2.3.2 High growth opportunities in emerging markets
      • 5.2.3.3 Integration with continuous and accelerated bioprocessing
      • 5.2.3.4 Rising outsourcing to CROs and CDMOs
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complexity in sample preparation and assay validation
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.4.2 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS, BY REGION, 2022-2024
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • 5.6.1 ROLE IN ECOSYSTEM
  • 5.7 INVESTMENT & FUNDING SCENARIO
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Quantitative PCR (qPCR)
      • 5.8.1.2 Droplet digital PCR (ddPCR)
      • 5.8.1.3 Next-generation sequencing (NGS)
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 Automated magnetic bead-based DNA extraction
      • 5.8.2.2 Capillary electrophoresis
      • 5.8.2.3 Nanopore sequencing
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 High-performance liquid chromatography (HPLC)
      • 5.8.3.2 Electron microscopy
      • 5.8.3.3 Mass spectrometry
  • 5.9 PATENT ANALYSIS
    • 5.9.1 LIST OF KEY PATENTS
  • 5.10 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.11 REGULATORY ANALYSIS
    • 5.11.1 REGULATORY FRAMEWORK
      • 5.11.1.1 North America
        • 5.11.1.1.1 US
        • 5.11.1.1.2 Canada
      • 5.11.1.2 Europe
        • 5.11.1.2.1 UK
      • 5.11.1.3 Asia Pacific
        • 5.11.1.3.1 China
        • 5.11.1.3.2 Japan
        • 5.11.1.3.3 India
    • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 BARGAINING POWER OF SUPPLIERS
    • 5.12.2 BARGAINING POWER OF BUYERS
    • 5.12.3 THREAT OF NEW ENTRANTS
    • 5.12.4 THREAT OF SUBSTITUTES
    • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.13.2 KEY BUYING CRITERIA, BY END USER
  • 5.14 IMPACT OF AI/GEN AI ON RESIDUAL DNA TESTING MARKET
    • 5.14.1 MARKET POTENTIAL OF AI IN RESIDUAL DNA TESTING
    • 5.14.2 AI USE CASES
    • 5.14.3 KEY COMPANIES IMPLEMENTING AI/GEN AI
    • 5.14.4 FUTURE OF AI/GEN AI IN RESIDUAL DNA TESTING MARKET
  • 5.15 TRADE DATA ANALYSIS
    • 5.15.1 IMPORT DATA FOR HS CODE 9027, 2020-2024
    • 5.15.2 EXPORT DATA FOR HS CODE 9027, 2020-2024
  • 5.16 IMPACT OF 2025 US TARIFF ON RESIDUAL DNA TESTING MARKET
    • 5.16.1 KEY TARIFF RATES
    • 5.16.2 PRICE IMPACT ANALYSIS
    • 5.16.3 IMPACT ON COUNTRIES/REGIONS
      • 5.16.3.1 North America
        • 5.16.3.1.1 US
      • 5.16.3.2 Europe
      • 5.16.3.3 Asia Pacific
      • 5.16.3.4 Rest of the World
    • 5.16.4 IMPACT ON END-USE INDUSTRIES
      • 5.16.4.1 Pharmaceutical & biotechnology companies
      • 5.16.4.2 CROs & CDMOs
      • 5.16.4.3 Academic & research institutes

6 RESIDUAL DNA TESTING MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 PRODUCTS
    • 6.2.1 CONSUMABLES
      • 6.2.1.1 Increasing focus on development of biologics and biosimilars to propel segment growth
    • 6.2.2 INSTRUMENTS & SOFTWARE
      • 6.2.2.1 Continuous advancement in analytical technologies to fuel segment growth
  • 6.3 SERVICES
    • 6.3.1 STRINGENT REGULATORY STANDARDS TO PROMOTE MARKET GROWTH

7 RESIDUAL DNA TESTING MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
  • 7.2 FINAL PRODUCT RELEASE TESTING
    • 7.2.1 FAVORABLE REGULATORY MANDATES AND BIOLOGICS INNOVATION TO FUEL MARKET GROWTH
  • 7.3 BULK LOT RELEASE TESTING
    • 7.3.1 INCREASING BIOLOGIC COMPLEXITY TO FUEL MARKET GROWTH
  • 7.4 RAW MATERIAL TESTING
    • 7.4.1 ENHANCED FOCUS ON PRODUCT SAFETY AND REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH

8 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
  • 8.2 POLYMERASE CHAIN REACTION
    • 8.2.1 HIGH THROUGHPUT DETECTION TO SUPPORT SEGMENT DOMINANCE
  • 8.3 THRESHOLD ASSAYS
    • 8.3.1 HIGH SPECIFICITY OF DNA DETECTION AT LOW CONCENTRATION TO FUEL MARKET GROWTH
  • 8.4 DNA PROBE HYBRIDIZATION
    • 8.4.1 EASY-TO-USE PORTFOLIO TO BOOST ADOPTION OF DNA PROBE HYBRIDIZATION
  • 8.5 OTHER TECHNOLOGIES

9 RESIDUAL DNA TESTING MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
  • 9.2 MONOCLONAL ANTIBODIES
    • 9.2.1 EXPANSION OF BIOSIMILAR PIPELINE TO AID MARKET GROWTH
  • 9.3 CELL & GENE THERAPY
    • 9.3.1 RISING POPULARITY OF VIRAL VECTOR-BASED SYSTEMS AND INCREASING REGULATORY APPROVALS TO AID MARKET GROWTH
  • 9.4 VACCINES
    • 9.4.1 PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
  • 9.5 OTHER APPLICATIONS

10 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 HIGH BIOPHARMACEUTICAL R&D SPENDING AND INCREASED REGULATORY PRESSURE TO FUEL MARKET GROWTH
  • 10.3 CROS & CDMOS
    • 10.3.1 FOCUS ON BIOLOGICS DEVELOPMENT AND CDMO FACILITY EXPANSION TO BOOST MARKET GROWTH
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    • 10.4.1 SURGE IN R&D ACTIVITIES FOR DEVELOPMENT OF ADVANCED THERAPIES TO DRIVE MARKET GROWTH

11 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 SURGE IN R&D INVESTMENTS IN BIOPHARMACEUTICAL INNOVATION TO PROPEL MARKET GROWTH
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
    • 11.3.1 SSLIMITED IN-HOUSE CAPABILITIES TO DRIVE OUTSOURCING

12 RESIDUAL DNA TESTING MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 US to dominate North American residual DNA testing market during study period
    • 12.2.3 CANADA
      • 12.2.3.1 Increasing government support for biologics manufacturing and rising research funding to propel market growth
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Increasing investments in biopharma and rising focus on developing manufacturing capabilities to drive market
    • 12.3.3 UK
      • 12.3.3.1 Booming life science industry and growing focus on vaccine development to aid market growth
    • 12.3.4 FRANCE
      • 12.3.4.1 Growing biotechnology sector and rising research funding to drive market
    • 12.3.5 ITALY
      • 12.3.5.1 High R&D investments in life sciences research to augment market growth
    • 12.3.6 SPAIN
      • 12.3.6.1 Increasing number of biotech companies to favor market growth
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 High R&D expenditure and favorable strategic alliances to propel market growth
    • 12.4.3 JAPAN
      • 12.4.3.1 Favorable government initiatives for drug development to support market growth
    • 12.4.4 INDIA
      • 12.4.4.1 Increasing R&D investments and funding for life science research to support market growth
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Increasing strategic alliances and investments to spur market growth
    • 12.4.6 AUSTRALIA
      • 12.4.6.1 Booming life science sector to fuel market growth
    • 12.4.7 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Substantial R&D investments by pharmaceutical companies to fuel market growth
    • 12.5.3 MEXICO
      • 12.5.3.1 Rising government support for biopharmaceutical production to drive market
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Kingdom of Saudi Arabia
        • 12.6.2.1.1 Increasing R&D investments in pharmaceutical industries to drive market
      • 12.6.2.2 UAE
        • 12.6.2.2.1 Investments in biopharma sector to offer growth opportunities
      • 12.6.2.3 Rest of GCC Countries
    • 12.6.3 REST OF MIDDLE EAST
  • 12.7 AFRICA
    • 12.7.1 RISING PREVALENCE OF CHRONIC DISEASES AND INCREASING FUNDING FOR BIOPHARMA SECTOR TO FUEL MARKET GROWTH
    • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RESIDUAL DNA TESTING MARKET
  • 13.3 REVENUE ANALYSIS, 2020-2024
  • 13.4 MARKET SHARE ANALYSIS, 2024
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 13.5.5.1 Company footprint
      • 13.5.5.2 Region footprint
      • 13.5.5.3 Offering footprint
      • 13.5.5.4 Technology footprint
      • 13.5.5.5 Test type footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 13.6.5.1 Detailed list of key startups/SMEs
      • 13.6.5.2 Competitive benchmarking of Key startups/SMEs
  • 13.7 COMPANY VALUATION & FINANCIAL METRICS
    • 13.7.1 FINANCIAL METRICS
    • 13.7.2 COMPANY VALUATION
  • 13.8 BRAND/PRODUCT COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES
    • 13.9.2 DEALS
    • 13.9.3 OTHER DEVELOPMENTS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 THERMO FISHER SCIENTIFIC INC.
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products/Services offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Expansions
        • 14.1.1.3.2 Other developments
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses & competitive threats
    • 14.1.2 CHARLES RIVER LABORATORIES
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products/Services offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Expansions
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses & competitive threats
    • 14.1.3 F. HOFFMANN-LA ROCHE LTD.
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products/Services offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Product launches
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses & competitive threats
    • 14.1.4 MERCK KGAA
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products/Services offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches
        • 14.1.4.3.2 Expansions
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Key strengths
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses & competitive threats
    • 14.1.5 MARAVAI LIFESCIENCES
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products/Services offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Deals
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Key strengths
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses & competitive threats
    • 14.1.6 EUROFINS SCIENTIFIC
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products/Services offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Deals
    • 14.1.7 BIO-RAD LABORATORIES, INC.
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products/Services offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Deals
    • 14.1.8 QIAGEN
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products/Services offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches
    • 14.1.9 FUJIFILM CORPORATION
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products/Services offered
    • 14.1.10 SGS SOCIETE GENERALE DE SURVEILLANCE SA.
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products/Services offered
    • 14.1.11 HILLGENE BIOPHARMA CO., LTD.
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products/Services offered
    • 14.1.12 REVVITY
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products/Services offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Product launches
    • 14.1.13 INTERTEK GROUP PLC
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products/Services offered
    • 14.1.14 SARTORIUS AG
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products/Services offered
    • 14.1.15 LONZA
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products/Services offered
    • 14.1.16 WUXI APPTEC
      • 14.1.16.1 Business overview
      • 14.1.16.2 Products/Services offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 TRANSGEN BIOTECH CO., LTD.
    • 14.2.2 EAGLEBIO
    • 14.2.3 YEASEN
    • 14.2.4 ACROBIOSYSTEMS
    • 14.2.5 CREATIVE BIOGENE
    • 14.2.6 MINERVA BIOLABS GMBH
    • 14.2.7 CREATIVE PROTEOMICS
    • 14.2.8 AVANCE BIOSCIENCES
    • 14.2.9 GENERI BIOTECH

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS